Roosa Kaarijärvi YOU? Author Swipe

Last 10y

DPYSL3B is a regulator of chemoresistance via DNA repair and metabolic reprogramming in prostate cancer Open

Roosa Kaarijärvi, Heidi Kaljunen, Nella Itkonen, Kseniia Bureiko, Kirsi Ketola · 2025

Prostate cancer is among the most common cancers worldwide. Aggressive, treatment-resistant subtypes including androgen receptor (AR) -negative and neuroendocrine prostate cancer, present a significant clinical challenge. Platinum-based ch…

Matrix stiffness modulates androgen response genes and chromatin state in prostate cancer Open

Roosa Kaarijärvi, Heidi Kaljunen, Onni Niemi, Mikko Räsänen, Ville Paakinaho , et al. · 2025

The interplay between the extracellular matrix (ECM) and prostate cancer has been shown to increase ECM stiffness, correlating with more aggressive disease forms. However, the impact of ECM stiffness on the androgen receptor (AR), a key ta…

SIX2 promotes cell plasticity via Wnt/β-catenin signalling in androgen receptor independent prostate cancer Open

Noora Leppänen, Heidi Kaljunen, Eerika Takala, Roosa Kaarijärvi, Petri I. Mäkinen , et al. · 2024

The use of androgen receptor (AR) inhibitors in prostate cancer gives rise to increased cellular lineage plasticity resulting in resistance to AR-targeted therapies. In this study, we examined the chromatin landscape of AR-positive prostat…

DPYSL5 is highly expressed in treatment-induced neuroendocrine prostate cancer and promotes lineage plasticity via EZH2/PRC2 Open

Roosa Kaarijärvi, Heidi Kaljunen, Lucia Nappi, Ladan Fazli, Sonia H.Y. Kung , et al. · 2024

Fanconi anemia pathway regulation by FANCI in prostate cancer Open

Heidi Kaljunen, Sinja Taavitsainen, Roosa Kaarijärvi, Ville Paakinaho, Matti Nykter , et al. · 2023

Prostate cancer is one of the leading causes of death among men worldwide, and thus, research on the genetic factors enabling the formation of treatment-resistant cancer cells is crucial for improving patient outcomes. Here, we report a ce…

SIX2 promotes cell plasticity via Wnt/ß-catenin signalling in androgen receptor independent prostate cancer Open

Noora Leppänen, Heidi Kaljunen, Roosa Kaarijärvi, Ilkka Paatero, Ville Paakinaho , et al. · 2023

Supplementary Table 3 from Subclone Eradication Analysis Identifies Targets for Enhanced Cancer Therapy and Reveals L1 Retrotransposition as a Dynamic Source of Cancer Heterogeneity Open

Kirsi Ketola, Heidi Kaljunen, Sinja Taavitsainen, Roosa Kaarijärvi, Emmi Järvelä , et al. · 2023

qPCR primers used for L1-ORF1, L1-ORF2, FANCI, and GAPDH.

Data from Subclone Eradication Analysis Identifies Targets for Enhanced Cancer Therapy and Reveals L1 Retrotransposition as a Dynamic Source of Cancer Heterogeneity Open

Kirsi Ketola, Heidi Kaljunen, Sinja Taavitsainen, Roosa Kaarijärvi, Emmi Järvelä , et al. · 2023

Treatment-eradicated cancer subclones have been reported in leukemia and have recently been detected in solid tumors. Here we introduce Differential Subclone Eradication and Resistance (DSER) analysis, a method developed to identify molecu…

Supplementary Table 5 from Subclone Eradication Analysis Identifies Targets for Enhanced Cancer Therapy and Reveals L1 Retrotransposition as a Dynamic Source of Cancer Heterogeneity Open

Kirsi Ketola, Heidi Kaljunen, Sinja Taavitsainen, Roosa Kaarijärvi, Emmi Järvelä , et al. · 2023

Concordance of L1 insertion calls from the current study with insertion calls reported in Tubio et al.

Supplementary Table 4 from Subclone Eradication Analysis Identifies Targets for Enhanced Cancer Therapy and Reveals L1 Retrotransposition as a Dynamic Source of Cancer Heterogeneity Open

Kirsi Ketola, Heidi Kaljunen, Sinja Taavitsainen, Roosa Kaarijärvi, Emmi Järvelä , et al. · 2023

SNVs and indels in A34 subclones. Eradicated subclones are subclone numbers 12, 13, 14, and 15.

Supplementary Table 1 from Subclone Eradication Analysis Identifies Targets for Enhanced Cancer Therapy and Reveals L1 Retrotransposition as a Dynamic Source of Cancer Heterogeneity Open

Kirsi Ketola, Heidi Kaljunen, Sinja Taavitsainen, Roosa Kaarijärvi, Emmi Järvelä , et al. · 2023

L1 retrotransposition evens identified by TraFiC analysis in A34 in the current study.

Supplementary Table 4 from Subclone Eradication Analysis Identifies Targets for Enhanced Cancer Therapy and Reveals L1 Retrotransposition as a Dynamic Source of Cancer Heterogeneity Open

Kirsi Ketola, Heidi Kaljunen, Sinja Taavitsainen, Roosa Kaarijärvi, Emmi Järvelä , et al. · 2023

SNVs and indels in A34 subclones. Eradicated subclones are subclone numbers 12, 13, 14, and 15.

Supplementary Material-SM1 from Subclone Eradication Analysis Identifies Targets for Enhanced Cancer Therapy and Reveals L1 Retrotransposition as a Dynamic Source of Cancer Heterogeneity Open

Kirsi Ketola, Heidi Kaljunen, Sinja Taavitsainen, Roosa Kaarijärvi, Emmi Järvelä , et al. · 2023

Ketola et al Supplementary Material

Supplementary Table 3 from Subclone Eradication Analysis Identifies Targets for Enhanced Cancer Therapy and Reveals L1 Retrotransposition as a Dynamic Source of Cancer Heterogeneity Open

Kirsi Ketola, Heidi Kaljunen, Sinja Taavitsainen, Roosa Kaarijärvi, Emmi Järvelä , et al. · 2023

qPCR primers used for L1-ORF1, L1-ORF2, FANCI, and GAPDH.

Supplementary Material-SM1 from Subclone Eradication Analysis Identifies Targets for Enhanced Cancer Therapy and Reveals L1 Retrotransposition as a Dynamic Source of Cancer Heterogeneity Open

Kirsi Ketola, Heidi Kaljunen, Sinja Taavitsainen, Roosa Kaarijärvi, Emmi Järvelä , et al. · 2023

Ketola et al Supplementary Material

Data from Subclone Eradication Analysis Identifies Targets for Enhanced Cancer Therapy and Reveals L1 Retrotransposition as a Dynamic Source of Cancer Heterogeneity Open

Kirsi Ketola, Heidi Kaljunen, Sinja Taavitsainen, Roosa Kaarijärvi, Emmi Järvelä , et al. · 2023

Treatment-eradicated cancer subclones have been reported in leukemia and have recently been detected in solid tumors. Here we introduce Differential Subclone Eradication and Resistance (DSER) analysis, a method developed to identify molecu…

Supplementary Table 2 from Subclone Eradication Analysis Identifies Targets for Enhanced Cancer Therapy and Reveals L1 Retrotransposition as a Dynamic Source of Cancer Heterogeneity Open

Kirsi Ketola, Heidi Kaljunen, Sinja Taavitsainen, Roosa Kaarijärvi, Emmi Järvelä , et al. · 2023

FANCI siRNA experimental data depicted in Supp Fig S3

Supplementary Table 1 from Subclone Eradication Analysis Identifies Targets for Enhanced Cancer Therapy and Reveals L1 Retrotransposition as a Dynamic Source of Cancer Heterogeneity Open

Kirsi Ketola, Heidi Kaljunen, Sinja Taavitsainen, Roosa Kaarijärvi, Emmi Järvelä , et al. · 2023

L1 retrotransposition evens identified by TraFiC analysis in A34 in the current study.

Supplementary Table 5 from Subclone Eradication Analysis Identifies Targets for Enhanced Cancer Therapy and Reveals L1 Retrotransposition as a Dynamic Source of Cancer Heterogeneity Open

Kirsi Ketola, Heidi Kaljunen, Sinja Taavitsainen, Roosa Kaarijärvi, Emmi Järvelä , et al. · 2023

Concordance of L1 insertion calls from the current study with insertion calls reported in Tubio et al.

Supplementary Table 2 from Subclone Eradication Analysis Identifies Targets for Enhanced Cancer Therapy and Reveals L1 Retrotransposition as a Dynamic Source of Cancer Heterogeneity Open

Kirsi Ketola, Heidi Kaljunen, Sinja Taavitsainen, Roosa Kaarijärvi, Emmi Järvelä , et al. · 2023

FANCI siRNA experimental data depicted in Supp Fig S3

Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse Open

Sinja Taavitsainen, Nikolai Engedal, Shaolong Cao, Florian Handle, Andrew Erickson , et al. · 2021

Subclone Eradication Analysis Identifies Targets for Enhanced Cancer Therapy and Reveals L1 Retrotransposition as a Dynamic Source of Cancer Heterogeneity Open

Kirsi Ketola, Heidi Kaljunen, Sinja Taavitsainen, Roosa Kaarijärvi, Emmi Järvelä , et al. · 2021

Treatment-eradicated cancer subclones have been reported in leukemia and have recently been detected in solid tumors. Here we introduce Differential Subclone Eradication and Resistance (DSER) analysis, a method developed to identify molecu…

Single-cell ATAC and RNA sequencing reveal pre-existing and persistent subpopulations of cells associated with relapse of prostate cancer Open

Sinja Taavitsainen, Nikolai Engedal, Shaolong Cao, Florian Handle, Andrew Erickson , et al. · 2021

Single-cell ATAC and RNA sequencing reveal pre-existing and persistent subpopulations of cells associated with relapse of prostate cancer Open

Sinja Taavitsainen, Nikolai Engedal, Shaolong Cao, Florian Handle, Andrew Erickson , et al. · 2021

Prostate cancer is profoundly heterogeneous and patients would benefit from methods that stratify clinically indolent from more aggressive forms of the disease. We employed single-cell assay for transposase-accessible chromatin (ATAC) and …

Molecular and Functional Links between Neurodevelopmental Processes and Treatment-Induced Neuroendocrine Plasticity in Prostate Cancer Progression Open

Roosa Kaarijärvi, Heidi Kaljunen, Kirsi Ketola · 2021

Neuroendocrine plasticity and treatment-induced neuroendocrine phenotypes have recently been proposed as important resistance mechanisms underlying prostate cancer progression. Treatment-induced neuroendocrine prostate cancer (t-NEPC) is h…

Fetching topic information...